Wedbush analyst Liana Moussatos reiterated an Outperform rating and $423 acquisition value on Intercept Pharmaceuticals (NASDAQ: ICPT) after the Gastrointestinal ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

FBR Capital Remains on Sidelines with Intercept Pharmaceuticals (ICPT) Following FDA Panel BackingApril 8, 2016 9:51 AM Oppenheimer Reiterates $309 PT on Intercept Pharma (ICPT) Following FDA Panel BackingApril 8, 2016 8:25 AM Panel Backing of OCA was Expected, Leerink Partners Says; Remains SidelinedApril 8, 2016 7:34 AM Intercept (ICPT) AdCom Couldn't Have Gone Better, Baird Says; Notes Gilead (GILD) Exec in the AudienceApril 8, 2016 7:02 AM Morgan Stanley Cuts Intercept (ICPT) to Underweight on Ocaliva Label/Launch Concerns, NASH Read-ThroughApril 8, 2016 6:56 AM Needham & Company Reiterates Buy on Intercept Pharma (ICPT) Following Positive FDA Panel Vote on Obeticholic AcidApril 8, 2016 6:53 AM Intercept (ICPT) Announces Unanimous FDA Committee Recommendation for Accelerated Approval of OCA as PBC TreatmentApril 7, 2016 5:02 PM FDA Advisory Committee Unanimously Recommends Accelerated Approval of Ocaliva™ (obeticholic acid) for the Treatment of PBCApril 7, 2016 5:00 PM Intercept Pharma's (ICPT) OCA wins FDA panel backing in PBCApril 7, 2016 3:49 PM